282 completed, 83 terminated, 76 recruiting, 59 unknown. 334 Phase 2, 149 Phase 3, 145 Phase 1, 14 Not applicable, 14 Phase 4.
Follow 5-fluorouracil: new trials by email Literature Review of 5-fluorouracil trials Research Report on 5-fluorouracil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 125 | 2027-02-03 | 2026-08-06 |
| Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma Biospecimen Collection, Echocardiography Test, Fluorouracil - Childhood Posterior Fossa Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 70 | 2026-12-11 | 2026-09-30 |
| Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer Biospecimen Collection, Computed Tomography, Fluorouracil - Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 30 | 2026-12-01 | 2026-09-02 |
| A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 4 | Not yet recruiting | Astellas Pharma Global Development, Inc. | 50 | 2026-11-30 | 2026-09-21 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 229 | 2026-11-01 | 2026-10-16 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-27 | 2026-10-08 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Pathological Response to Perioperative FLOT in Gastric Adenocarcinoma FLOT Chemotherapy - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Fundación Santa Fe de Bogota | 90 | 2026-10-01 | 2026-10-05 | |
| A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation Olomorasib, Cetuximab, Oxaliplatin - Colorectal Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 50 | 2026-10-01 | 2026-10-15 |
| A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors ASP388B, Pembrolizumab, Carboplatin - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 392 | 2026-09-02 | 2026-09-18 |
| Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 34 | 2026-09-01 | 2026-06-05 |
| Fractional CO2 Laser vs Dermabrasion With 5-Fluorouracil for Acquired Leukoderma Fractional CO2 Laser, Dermabrasion, 5-Fluorouracil - Leukoderma, Hypopigmentation | Not applicable | Not yet recruiting | Al-Azhar University | 16 | 2026-08-26 | 2026-09-24 |
| Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature Oxaliplatin, Irinotecan, Folinic acid - Pancreatic Ductal Adenocarcinoma | Phase 3 | Recruiting | John Neoptolemos | 394 | 2026-08-17 | 2026-08-27 |
| Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients Ivonescimab +mFOLFOXIRI +celecoxib - Colorectal Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 45 | 2026-08-10 | 2026-09-09 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer Abemaciclib, Oxaliplatin, Calcium Folinate - Liver Metastases From Colorectal Cancer (mCRC) | Phase 2 | Enrolling by invitation | Fudan University | 16 | 2026-07-30 | 2026-07-22 |
| FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC FOLFIRI + bevacizumab + QL1706, FOLFIRI + bevacizumab - Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC) | Phase 3 | Not yet recruiting | Sun Yat-sen University | 270 | 2026-07-30 | 2026-07-27 |
| A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) BL-B01D1, Tislelizumab, 5-Fluorouracil - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 90 | 2026-06-09 | 2026-07-16 |
Showing 20 of 604. Sign in to see all of them.
Colorectal Neoplasms (130) · Rectal Neoplasms (70) · Stomach Neoplasms (67) · Pancreatic Neoplasms (65) · Colonic Neoplasms (54) · Esophageal Neoplasms (41) · Neoplasm Metastasis (31) · Breast Neoplasms (30) · Neoplasms (30) · Squamous Cell Carcinoma of Head and Neck (29) · Adenocarcinoma Of Esophagus (20) · Adenocarcinoma (14) · Carcinoma, Squamous Cell (13) · Head and Neck Neoplasms (13) · Anus Neoplasms (11)
National Cancer Institute (NCI) (63) · M.D. Anderson Cancer Center (34) · Sun Yat-sen University (16) · Hoffmann-La Roche (14) · City of Hope Medical Center (11) · ImmunityBio, Inc. (11) · Merck Sharp & Dohme LLC (10) · Sanofi (10) · ECOG-ACRIN Cancer Research Group (9) · SCRI Development Innovations, LLC (9) · Dana-Farber Cancer Institute (8) · SWOG Cancer Research Network (8) · AstraZeneca (7) · Eli Lilly and Company (7) · Fudan University (7)
United States (370) · China (96) · Italy (59) · Germany (57) · Canada (53) · Spain (50) · France (47) · United Kingdom (42) · Japan (41) · South Korea (39) · Taiwan (33) · Australia (31) · Poland (30) · Puerto Rico (29) · Belgium (28)
Marwan Fakih (5) · Yanhong Deng, M.D. (5) · Norman Wolmark, MD (4) · Jaffer Ajani, MD (3) · John Souglakos, MD (3) · Marshall Posner, MD (3) · Masahiro Asaka, MD, PhD (3) · Yelena Janjigian, MD (3) · Afsaneh Barzi (2)
PMID 31268130, PMID 33356421, PMID 35623069, PMID 36306483, PMID 21997132, PMID 28006055, PMID 31811950, PMID 37957132, PMID 38315963, PMID 40207789, PMID 11098486, PMID 14745444, PMID 15774775, PMID 15930421, PMID 16532436, PMID 16648506, PMID 16945170, PMID 17264338, PMID 17470851, PMID 17470859, PMID 17853393, PMID 19525947, PMID 19738454, PMID 20030854, PMID 20045791, PMID 20233444, PMID 20670978, PMID 20718753, PMID 20876799, PMID 20881648, PMID 21121833, PMID 21208843, PMID 21422418, PMID 21443688, PMID 21844504, PMID 21859995, PMID 21903473, PMID 22178121, PMID 22212563, PMID 22240792, PMID 22474202, PMID 22503032, PMID 22884505, PMID 22895629, PMID 23063354, PMID 23233715, PMID 23246022, PMID 23293700, PMID 23479384, PMID 23490654
U10CA180820 (13), U10CA021115 (9), U10CA180868 (9), 2023 (8), U10CA032102 (8), U10CA180888 (8), 2017 (7), 2015 (5), 2018 (5), P30CA033572 (5), U10CA031946 (5), P30CA016672 (4), P30CA036727 (4), U10CA012027 (4), U10CA180821 (4)